Hologic, Inc. (HOLX)
HOLX Stock Price Chart
Explore Hologic, Inc. interactive price chart. Choose custom timeframes to analyze HOLX price movements and trends.
HOLX Company Profile
Discover essential business fundamentals and corporate details for Hologic, Inc. (HOLX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
IPO Date
1 Mar 1990
Employees
7.06K
Website
https://www.hologic.comCEO
Stephen P. MacMillan
Description
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
HOLX Financial Timeline
Browse a chronological timeline of Hologic, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 3 Feb 2026
Upcoming earnings on 3 Nov 2025
EPS estimate is $1.10.
Earnings released on 30 Jul 2025
EPS came in at $1.08 surpassing the estimated $1.05 by +2.86%, while revenue for the quarter reached $1.02B , missing expectations by -0.99%.
Earnings released on 1 May 2025
EPS came in at $1.03 surpassing the estimated $1.02 by +0.98%, while revenue for the quarter reached $1.01B , beating expectations by +0.48%.
Earnings released on 5 Feb 2025
EPS came in at $1.03 surpassing the estimated $1.02 by +0.98%, while revenue for the quarter reached $1.02B , missing expectations by -0.05%.
Earnings released on 4 Nov 2024
EPS came in at $1.01 matching the estimated $1.01, while revenue for the quarter reached $987.90M , beating expectations by +0.99%.
Earnings released on 29 Jul 2024
EPS came in at $1.06 surpassing the estimated $1.02 by +3.92%, while revenue for the quarter reached $1.01B , beating expectations by +0.96%.
Earnings released on 2 May 2024
EPS came in at $1.03 surpassing the estimated $0.98 by +5.32%, while revenue for the quarter reached $1.02B , beating expectations by +1.60%.
Earnings released on 1 Feb 2024
EPS came in at $0.98 surpassing the estimated $0.95 by +3.16%, while revenue for the quarter reached $1.01B , beating expectations by +2.74%.
Earnings released on 9 Nov 2023
EPS came in at $0.89 surpassing the estimated $0.85 by +4.71%, while revenue for the quarter reached $945.30M , beating expectations by +0.56%.
Earnings released on 31 Jul 2023
EPS came in at $0.93 surpassing the estimated $0.88 by +5.68%, while revenue for the quarter reached $984.40M , beating expectations by +2.27%.
Earnings released on 1 May 2023
EPS came in at $1.06 surpassing the estimated $0.88 by +20.45%, while revenue for the quarter reached $1.03B , beating expectations by +7.06%.
Earnings released on 1 Feb 2023
EPS came in at $1.07 surpassing the estimated $0.90 by +18.89%, while revenue for the quarter reached $1.07B , beating expectations by +6.91%.
Earnings released on 31 Oct 2022
EPS came in at $0.82 surpassing the estimated $0.62 by +32.26%, while revenue for the quarter reached $953.20M , beating expectations by +10.57%.
Earnings released on 27 Jul 2022
EPS came in at $0.95 surpassing the estimated $0.71 by +33.80%, while revenue for the quarter reached $1.00B , beating expectations by +11.00%.
Earnings released on 27 Apr 2022
EPS came in at $2.07 surpassing the estimated $1.60 by +29.37%, while revenue for the quarter reached $1.44B , beating expectations by +11.39%.
Earnings released on 2 Feb 2022
EPS came in at $2.17 surpassing the estimated $1.28 by +69.53%, while revenue for the quarter reached $1.47B , beating expectations by +23.31%.
Earnings released on 1 Nov 2021
EPS came in at $1.61 surpassing the estimated $1.01 by +59.41%, while revenue for the quarter reached $1.32B , beating expectations by +13.13%.
Earnings released on 28 Jul 2021
EPS came in at $1.33 surpassing the estimated $1.12 by +18.75%, while revenue for the quarter reached $1.17B , beating expectations by +13.69%.
Earnings released on 28 Apr 2021
EPS came in at $2.59 falling short of the estimated $2.62 by -1.15%, while revenue for the quarter reached $1.54B , beating expectations by +0.81%.
Earnings released on 27 Jan 2021
EPS came in at $2.86 surpassing the estimated $2.17 by +31.80%, while revenue for the quarter reached $1.61B , beating expectations by +46.62%.
Earnings released on 4 Nov 2020
EPS came in at $2.07 surpassing the estimated $1.22 by +69.67%, while revenue for the quarter reached $1.35B , beating expectations by +33.23%.
HOLX Stock Performance
Access detailed HOLX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.